Secondary Logo

Journal Logo

Correspondence

Predictive factors for high-flow nasal cannula failure

Taking a closer look

Nair, Abhijit S.1; Esquinas, Antonio M.2

Author Information
doi: 10.4103/lungindia.lungindia_51_22
  • Open

Sir,

We have read with great interest the article by Lun et al.[1] where the researchers evaluated the role of high-flow nasal cannula (HFNC) in adult patients with acute hypoxaemic respiratory failure (AHRF). The authors concluded that the respiratory rate-oxygenation (ROX) index at 12 h serves as a valuable tool to monitor the responsiveness to HFNC treatment.[2] We consider that this article provides great information for clinical practice and the ability to detect situations of failure of the HFNC that avoid an increase in mortality. However, we consider that there are some aspects in this study that can be analysed to make a correct extrapolation of the results in clinical practice. These aspects deserve to be analysed.

  1. Gas exchange- meaning of pH: In this model of factors associated with failure, it is interesting to know the value and meaning of higher pH on the day of HFNC commencement. As per recommendations from several societies, patients with a pH less than 7.30 should not be offered HFNC. Although the authors have provided a value of pH in the table (7.46 [7.42–7.49]), it does not appear to be the value at the time of commencement of HFNC.[3] In the article, it is observed that the flow of HFNC at commencement in liters per minute (LPM) was 40 and this aspect could not be related to level of nasal high flow. We consider that it may be influenced by factors associated with an excess of hyperventilation or bicarbonate levels.
  2. Non-invasive ventilation (NIV) versus oxygen therapy modalities before analysis. The authors considered the modality of O2 delivery before HFNC. This is an important aspect that may impact the global results because we do not know if these elements can affect the value of ROX index in its predictive capacity in this study.[4]
  3. HFNC setting. Time from admission to HFNC in the intensive care unit (ICU). There was no difference in the time from admission to HFNC, that is, 1.01 (0.35–2.02) 0.68 (0.17–0.68) 0.422. This aspect is interesting because it is not addressed by previous studies, where the early use of HFNC is promoted. In this line, it is important to know that these results are analysed in patients in the ICU, and it is unknown what criteria were used by the authors for admission to the ICU and if they were applied outside the ICU as an equally predictive factor.[5]

To conclude, the predictive factors mentioned by us in this letter also deserve attention because we believe it is important in arriving at a definitive conclusion.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Lun CT, Leung CK, Shum HP, So SO Predictive factors for high-flow nasal cannula failure in acute hypoxemic respiratory failure in an intensive care unit Lung India 2022 39 5–11
2. Goh KJ, Chai HZ, Ong TH, Sewa DW, Phua GC, Tan QL Early prediction of high flow nasal cannula therapy outcomes using a modified ROX index incorporating heart rate J Intensive Care 2020 8 41 doi:10.1186/s40560-020-00458-z
3. Yuste ME, Moreno O, Narbona S, Acosta F, Peñas L, Colmenero M Efficacy and safety of high-flow nasal cannula oxygen therapy in moderate acute hypercapnic respiratory failure. Eficácia e segurança da oxigenoterapia com cânula nasal de alto fluxo na insuficiência respiratória hipercápnica moderada aguda Rev Bras Ter Intensiva 2019 31 156–63
4. Xu JQ, Su LX, Yan P, Hu XS, Wen RX, Xiao K, et al Expert consensus on clinical standardized application of high-flow nasal cannula oxygen therapy in adults Chin Med J (Engl) 2020 133 1322–24
5. MacéJ , Marjanovic N, Faranpour F, Mimoz O, Frerebeau M, Violeau M, et al Early high-flow nasal cannula oxygen therapy in adults with acute hypoxemic respiratory failure in the ED:A before-after study Am J Emerg Med 2019 37 2091–6
© 2022 Lung India | Published by Wolters Kluwer – Medknow